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Abstract
OpenTrials is a collaborative and open database for all available structured data and documents on all clinical trials,
threaded together by individual trial. With a versatile and expandable data schema, it is initially designed to host
and match the following documents and data for each trial: registry entries; links, abstracts, or texts of academic
journal papers; portions of regulatory documents describing individual trials; structured data on methods and
results extracted by systematic reviewers or other researchers; clinical study reports; and additional documents such
as blank consent forms, blank case report forms, and protocols. The intention is to create an open, freely re-usable
index of all such information and to increase discoverability, facilitate research, identify inconsistent data, enable
audits on the availability and completeness of this information, support advocacy for better data and drive up
standards around open data in evidence-based medicine. The project has phase I funding. This will allow us to
create a practical data schema and populate the database initially through web-scraping, basic record linkage
techniques, crowd-sourced curation around selected drug areas, and import of existing sources of structured and
documents. It will also allow us to create user-friendly web interfaces onto the data and conduct user engagement
workshops to optimise the database and interface designs. Where other projects have set out to manually and
perfectly curate a narrow range of information on a smaller number of trials, we aim to use a broader range of
techniques and attempt to match a very large quantity of information on all trials. We are currently seeking
feedback and additional sources of structured data.
Background
Trials are used to inform decision making, but there are
several ongoing problems with information management
on clinical trials, including publication bias, selective
outcome reporting, lack of information on methodo-
logical flaws, and duplication of effort for search and ex-
traction of data, which have a negative impact on patient
care. Randomised trials are used to detect differences be-
tween treatments because they are less vulnerable to
confounding, and because biases can be minimised
within the trial itself. The broader structural problems
external to each individual trial result in additional
biases, which can exaggerate or attenuate the apparent
benefits of treatments.
To take the example of publication bias, the results of
trials are commonly and legally withheld from doctors,
researchers and patients, more so when they have un-
welcome results [1, 2], and there are no clear data on
how much is missing for each treatment, sponsor, re-
search site, or investigator [3], which undermines efforts
at audit and accountability. Information that is publicly
available in strict legal terms can still be difficult to iden-
tify and access if, for example, it is contained in a poorly
indexed regulatory document or a results portal that is
not commonly accessed [4, 5]. In addition to this, differ-
ent reports on the same trial can often describe incon-
sistent results because of, for example, diverse analytic
approaches to the same data in different reports or
undisclosed primary outcome switching and other forms
of misreporting [4, 6]. There is also considerable
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inefficiency and duplication of effort around extracting
structured data from trial reports to conduct systematic
reviews, for example, and around indexing these data to
make it more discoverable and more used. Lastly, al-
though large collections of structured “open data” on
clinical trials would be valuable for research and clinical
activity, including linkage to datasets other than those
on trials, there is little available and it can be hard to
search or access.
In 1999, Altman and Chalmers described a concept of
“threaded publications” [7], whereby all publications re-
lated to a trial could be matched together: the published
protocol, the results paper, secondary commentaries, and
so forth. This suggestion has been taken up by the Linked
Reports of Clinical Trials project, a collaboration of aca-
demic publishers which was launched in 2011 with the
aim of using the existing CrossMark system for storing
metadata on academic publications as a place where pub-
lishers can store a unique identifier (ID) on each trial to
create a thread of published academic journal articles [8].
We have obtained funding for phase I of a project that
expands this vision, going further than linking all
academic papers on each trial: an open database of all
structured data and documents on all clinical trials,
cross-referenced and indexed by trial. The intention is
to create a freely re-usable index of all such information
to increase discoverability, facilitate audit on accessibility
of information, increase demand for structured data, fa-
cilitate annotation, facilitate research, drive up standards
around open data in evidence-based medicine, and help
address inefficiencies and unnecessary duplication in
search, research, and data extraction. Presenting such in-
formation coherently will also make different sources
more readily comparable and auditable. The project will
be built as structured “open data”, a well-recognised
concept in information policy work described as “data
that can be freely used, modified, and shared by anyone
for any purpose” [9].
This article describes our specific plans, the types of
documents and data we will be including, our methods
for populating the database, and our proposed presenta-
tions of the data to various different types of users. We
do not have funding to manually populate the entire
database for all data and documents on all trials, and
such a task would likely be unmanageably large in any
case. In the first phase, we aim to create an empty data-
base with a sensible data schema, or structure, and then
populate this through a combination of donations of
existing sets of data on clinical trials, scraping and then
matching existing data on clinical trials, with the option
for users of the site to upload missing documents or
links, and manual curation for a subset of trials. We will
also create user-friendly windows onto this data. Our
project start date was April 2015; our first user
engagement workshop was in April 2015; and, after con-
sultation on features and design, our first major coding
phase will start in September 2015. We are keen to hear
from anyone with suggestions, feature requests, or criti-
cisms, as well as from anybody able to donate structured
data on clinical trials, as described below.
Data schema
A description of the main classes of documents and data
included is presented below and in Fig. 1. In overview,
where possible, we will be collecting and matching regis-
try entries; links, abstracts, or texts of academic journal
papers; portions of regulatory documents describing tri-
als; structured data extracted by systematic reviewers or
other researchers; clinical study reports; additional docu-
ments such as blank consent forms; and protocols.
Types of documents and data included
Registers are a valuable source of structured data on on-
going and completed trials. There are two main categor-
ies of register: industry registers, containing information
on some or all trials conducted by one company, and na-
tional registers, containing information on some or all
trials conducted in one territory or covered by one regu-
lator. National registers generally consist of structured
data on 20 standard data fields set out by the World
Health Organisation (WHO) [10]; industry and specialty
registers are more variable [11]. The WHO International
Clinical Trials Registry Platform is a “registry of regis-
ters” combining the contents of a large number of regis-
ters in one place [12]. The simple act of aggregating,
deduplicating, and then comparing registers can in itself
be valuable. For example, in preliminary coding and
matching work, we have found that trials listed in one
register as “completed” may be listed as “ongoing” in an-
other; thus, anyone looking only in the register where
the trial was “ongoing” would not have known that re-
sults were, in fact, overdue. Similarly, where the text
field for primary outcome has been changed during a
trial, this can be identified in serial data on one registry
and flagged up on the page for that trial. Registers pre-
senting structured data have consistent and clearly de-
noted fields containing information on features such as
the number of participants, the interventions (ideally
using standard dictionaries and data schemas for
consistency with other structured data), inclusion and
exclusion criteria, primary and secondary outcomes, lo-
cation of trial sites, and so forth. This information is
ready to be extracted, processed, or presented. As a very
simple example, after extracting this information, one
can calculate the total number of trial participants on an
intervention globally, restrict a search to include only
large trials, or facilitate search of ongoing trials within
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50 miles of a location, on a specific condition, where
data quality permits [13].
Academic journals are one source of information on
clinical trials, in the form of semi-structured free text,
although they have increasingly been found to be flawed
vehicles for such data. For example, they are less
complete than clinical study reports [14], inconsistent
with mandated structured data on registers [15], and
permissive on undisclosed switching of primary out-
comes [6] and other forms of misreporting [16]. Journal
articles on trials include other document types, such as
commentaries and protocols. Academic journal articles
reporting trial results can be matched against registry
entries through various imperfect techniques, such as
searching for trial ID numbers in metadata on
PubMed (for very recent publications only) while ap-
plying standard search filters for trials, or using rec-
ord linkage techniques on other features such as
intervention or population.
Regulatory documents are an important and often
neglected source of information on trials. Clinical study
reports are extremely lengthy documents produced for
industry-sponsored trials. They have a closely defined
structure, which academic researchers have recently
begun to access more frequently [14, 17]. At the other
end of the spectrum for length, there will often be free
text descriptions of the methods and results of clinical
trials mixed in with other information in bundles of
regulatory documents released by the U.S. Food and
Drug Administration and indexed on the Drugs@FDA
website [18] or as part of the European public assess-
ment report published by the European Medicines
Agency for approved uses of approved drugs [19]. These
documents are generally neglected by clinicians and re-
searchers [5], poorly indexed, and hard to access and
navigate. For example, the description of one trial may
be buried in a few paragraphs in the middle of a long
and poorly structured file, containing multiple docu-
ments, each covering multiple different issues around
the approval of a product [4].
Structured data on the results of clinical trials is avail-
able from two main sources: registers that accept results
reporting, such as ClinicalTrials.gov and ISRCTN (Inter-
national Standard Randomised Controlled Trial Num-
ber), and structured data that has been manually
extracted from free text reports on trials by researchers
conducting systematic reviews or other research. This
can include structured data on the characteristics of the
trial (such as number of participants or a description of
the interventions using standard dictionaries) or the
Fig. 1 Overview of OpenTrials data schema and information flow
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results of a trial (to populate fields in meta-analysis soft-
ware), as well as data on the conduct of a trial or its
methodological shortcomings; for example, many trials
have had their risk of bias graded on various aspects of
trial design using standard tools such as the Cochrane
Risk of Bias Assessment Tool. There is also a Systematic
Review Data Repository (SRDR) archiving structured
data that has been extracted manually in the course of
producing systematic reviews. SRDR is managed by the
Agency for Healthcare Research and Quality (AHRQ),
which has already begun to pool such data [20].
Trial paperwork includes protocols, lay summaries,
and statistical analysis plans, as well as documents often
currently regarded as “internal”, such as blank case re-
port forms, blank consent forms, ethical approval docu-
ments, and patient information sheets. These are
generally poorly accessible and rarely indexed, but they
can contain salient information. For example, it was only
by examination of case report forms that the team con-
ducting the Cochrane review on oseltamivir and compli-
cations of influenza were able to establish that the
diagnostic criterion for pneumonia was “patient self-
report” rather than more conventional methods such as
chest x-ray, sputum, and/or medical examination [21].
As another example, when presented with a trial in
which the control group received a treatment which
seems to be lower than the usual standard of care, a re-
searcher or other interested party may wish to see the
consent form to establish whether the benefits and risks
of participation were clearly explained to patients. Lastly,
ethics committee or institutional review board paper-
work may contain information on how any potential
risks were discussed or mitigated or may act as an add-
itional source of information to identify undisclosed
switching of primary and secondary endpoints. By pla-
cing all of this information side by side, identifying such
inconsistencies becomes more straightforward and
therefore may reasonably be expected to become more
commonplace.
Populating the database
Manually populating the database for all documents and
data on all trials would be desirable, but it would be a
major information curation project requiring very sig-
nificant financial support. We initially aim to populate
the database in sections, with breadth and depth in dif-
ferent areas, through a range of approaches, including
web-scraping, basic record linkage techniques, curated
crowd-sourcing, and imports or donations of existing
structured and linked data.
Importing publicly accessible structured data is a
straightforward way to initially seed a database of infor-
mation on clinical trials. For example, the entire data-
base of structured data on ClinicalTrials.gov can be
downloaded and re-used. This database contains struc-
tured data on features such as title, number of partici-
pants, inclusion and exclusion criteria, interventions,
outcomes, and so forth [22]. There are several other
sources of structured data that can be downloaded and
re-used under standard Creative Commons licenses for
non-commercial re-use with attribution, such as the
SRDR archive hosted by AHRQ [20]. Where structured
data or documents on trials are publicly accessible but
not available for download as a single coherent dataset,
web-scraping can be used. This is a well-established
technique whereby large quantities of structured data
can be downloaded from websites automatically using
scripts to visit large numbers of web pages sequentially
and to download data from tables in pages.
Once data about trials are obtained, the issue then be-
comes matching data on each individual trial from the
various different sources, such as matching a Clinical-
Trials.gov registry entry against a row of manually ex-
tracted data on results that has been downloaded from
SRDR. This is a record linkage issue, and there is a long
and established literature and code base on the subject
in other domains, such as patient records. Where two
records share a common ID, such as a clinical trial
ID number, they can simply be merged. If there is no
common unique identifier, then standard probabilistic
record linkage techniques can be used on various fea-
tures of the trial.
An extension of this technique can be used for tar-
geted web-scraping. For example, all academic papers in
PubMed published since 2007 that refer to a registered
trial should contain the trial registry ID in the XML data
of the PubMed entry (although compliance with this fea-
ture was poor initially and has improved over time).
International Committee of Medical Journal Editors
guidelines have stated since 2005 that all trial results re-
ported in journals should include the trial registry ID in
the abstract. Therefore, we can automate a search of
PubMed to identify academic publications with a given
trial ID and import or generate metadata on these docu-
ments to our thread for that trial, including the type of
publication (such as protocol, results, or commentary),
year of publication, author names, and journal title.
Linkage of PubMed and ClinicalTrials.gov has already
been successfully conducted elsewhere [23], and the use
of record linkage and targeted scraping techniques can
be extended to other data sources.
We will also facilitate curated and targeted crowdsour-
cing. On the main page for a trial, in our current design,
there is a list of documents and data we would like to
have for each trial and an icon denoting whether it is
present. If it is not present, there is an “upload arrow”.
As an illustration, where we have a trial thread that con-
tains a registry entry and an academic publication on
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results, but nothing more, then visitors can click to up-
load something such as a file containing structured data
on results, a link to a clinical study report that they have
located online, or a copy of a blank consent form. Each
upload requires metadata, checking, and credit where
necessary, with the option for users to flag where things
have been incorrectly associated with a trial. While par-
ticipatory data curation brings challenges, there is a large
and growing knowledge base on this approach, both
from Open Knowledge directly [24] and more broadly in
the open data community.
We have also initiated collaborations around donations
of structured data. There are many large datasets around
the world where some form of record linkage has been
done manually, or where structured data has been ex-
tracted from free text, to conduct a single piece of re-
search. For example, large samples of registry entries on
completed trials have been matched to academic publi-
cations and other sources of results on a specific search
date to create cohorts to investigate publication bias. We
have already arranged donations from researchers of
three datasets of varying sizes covering varying types of
data in various fields. Where disparate records pertain-
ing to a single trial have been matched manually in this
fashion, that matched data can be used in turn to valid-
ate automated record linkage techniques. It is important
that the contribution and investment by those who have
created such datasets be recognised and rewarded [25]
while also ensuring that maximum patient benefit is de-
rived from their work, minimising duplication of effort.
By maintaining metadata on provenance, we are able to
proactively give credit for all donated, imported, and ex-
ternally linked data, wherever data are presented or
downloadable. We are working with initial data donors
on ways to do this most effectively, such as by giving
credit to sources on the page for a specific trial and
automatically generating a bespoke list of required ac-
knowledgements and references for secondary users
when a batch of data is downloaded and re-used. Not-
ably, all researchers who have so far shared data in the
preliminary stage of OpenTrials have expressed enthusi-
asm for greater public benefit from the effort which
went into creating their dataset, especially as in some
cases the only previous output from the creation of a
large threaded dataset was a portion in a table in a
published academic paper. One researcher group has
expressed concern about their data being download-
able for re-use by other researchers before they have
extracted adequate value from it, which is a common
and legitimate concern in sharing raw data on all
academic work [25]; researchers are sharing, but with
a time delay.
Lastly, we are keen to populate the database manually,
as perfectly as possible, and for a small number of trials
to demonstrate the value of such a resource. There are
only limited resources for this in phase I funding, but we
will be guided in our choice of area by sources of fund-
ing and collaborations.
We currently intend to populate the database solely
for randomised trials in humans; however, because this
is principally a technical service rather than a manually
curated library, any increase in volume is unlikely to ma-
terially affect the feasibility of the project. We are there-
fore open to expanding this remit to include other types
of trials. For the same reason, there is no time limit on
the era of trials that can be added or on the geographical
territory covered.
Presenting the data
We have developed prototype presentations of the data
for different audiences and are currently running a series
of user engagement workshops to improve these. Initial
views are focused on search; researchers’ needs for indi-
vidual trials; patients’ needs for individual trials; and
overviews of performance metrics, which include trans-
parency metrics on how much information is available
for various classes of trial by sponsor, site, and so forth.
The webpage for researchers on a single trial is pre-
sented in Fig. 1. Across the top is the title and some
basic information about the trial, extracted from a regis-
try entry or a hierarchy of alternative sources. Below is a
series of icons showing the headline documents and
bundles of structured data that we would like to have on
all trials. These icons are green if the relevant data or
documents are present, and visitors can click through to
view them; they are amber if the documents have been
submitted or matched but not validated; and they are
red if they are outstanding. Upload arrows are avail-
able for all missing documents so that they can be
uploaded, as documents or links, by anyone who
wishes to contribute.
Below that, we have various different proposed
methods of presenting structured data. For example,
where a trial’s risk of bias has been manually assessed
somewhere and that data has been imported, we can dis-
play this in free text or icons to the visitor, showing
them at a glance whether the trial has significant meth-
odological shortcomings and what those shortcomings
were. We can also predict whether individual patient
data (IPD) should be available for the trial on request
and guide the visitor to the relevant portal (of which
there are currently at least 12), using simple algorithms
running on the structured data. For example, if a trial is
conducted after 2007, for a currently marketed product,
and sponsored by GlaxoSmithKline, the IPD should be
available on request through ClinicalStudyDataRequest.
com, and contextual explanatory notes for this service
are also provided. This may help to increase the use
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of such data, which is only requested infrequently at
present.
The presentation for patients (Fig. 2) is limited by the
quality of the data currently available for this audience,
but it has significant potential with greater user engage-
ment. For example, we can present search options for
ongoing trials for a given condition or a given drug, cov-
ering a given geographical area, filtered if necessary for
an individual’s eligibility by comparing their entered
demographic information against structured data on the
inclusion and exclusion criteria of each trial, where data
quality permits. Previous efforts to do this have been
hindered by the variably poor quality of information on
registries for non-specialist users. Here there are many
opportunities. The first is from record linkage. For ex-
ample, all trials must pass through an ethics committee,
Fig. 2 OpenTrials researcher view on a single trial (using mock data for feedback on proposed design only)
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and all ethics committees require a lay summary. Where
we can match the lay summary from ethics committee
paperwork, we can present it on the patient-facing page.
The second opportunity comes from using the option of
crowd-sourcing and annotation, as we can also permit
others to upload their own lay summaries. To this end,
we have begun negotiating with science communication
course leaders to work with them on using this as an ex-
ercise for their students, and are also keen that meth-
odological shortcomings in ongoing and completed trials
be communicated clearly to patients, with a view to de-
veloping a good trials guide. Here, as with other add-
itional features to the core service, our efforts will be
driven by opportunities for collaboration.
The overview of performance metrics (Fig. 3) demon-
strates the value of having a large quantity of structured
data in one place. For example, we can trivially produce
dashboards reporting numbers of ongoing and com-
pleted trials but also, for areas or drugs where the data
is reasonably complete, present metrics on transparency,
such as showing how much information is currently
missing for a given drug, sponsor, institution, investiga-
tor, and so forth. Such leader boards may be instrumen-
tal in driving up standards on transparency [3].
Some use cases
We envisage a wide range of users exploring a wide range
of questions and are keen to hear from potential users
with specific feature requests early in the development
process to ensure that we can meet their needs. Some ex-
amples of use cases are presented here for illustration.
A researcher or clinician may wish to find out more
about a range of trials on a drug, searching by various
different features such as inclusion and exclusion criteria
to match a specific population. For each individual trial,
where it has already been manually graded for methodo-
logical rigour, the researcher is provided with this infor-
mation immediately. Where the trial has been included
in a systematic review, a link to the review is promin-
ently displayed. If IPD is available on request, the re-
searcher can see this immediately. Where the results on
a trial have been reported in multiple different places, a
researcher can rapidly review these side by side; if there
are discrepancies, these may be informative. For example,
there may be a more conservative analytic strategy used in
the regulatory filing than in the academic paper, resulting
in conflicting effect sizes or participant counts; the pri-
mary outcomes may be switched or conflict between dif-
ferent presentations of the results; or the names of
authors and investigators may vary widely between regis-
tration and various presentations of results. Each of these
elements may raise concerns for further investigation.
A patient interested in participating in a trial may visit
the site looking for trials in progress, in their local area,
and on their medical condition. A science communica-
tion or clinical trials master of science student may visit
the site to identify a trial that is lacking a lay summary
or expert review and then write one as a learning experi-
ence and for the benefit of the wider community. An
expert patient or policy officer working for a patient
group may research a range of trials on the medicines
taken by patients with their condition and find that there
are many trials completed for which apparently no re-
sults have been posted. They can conduct a brief search
for missing results and post any results they are able to
find. Should this search yield no results, or if a profes-
sional search has already been conducted on a recent
date and confirmed no results, then the patient or pa-
tient group can contact the sponsor, principal investiga-
tor (PI), or company, explaining that they represent
patients using this treatment and asking them to make
the results of the trial publicly accessible.
A healthcare worker in a developing country setting
may be told of an ongoing trial by a patient and be
shown a consent form or patient information sheet.
Such a person can upload a copy of that document, and
it will be entered into the queue of unresolved submitted
documents. Here it can be seen and checked whether it
matches an ongoing registered trial. If it appears to be
for an unregistered trial, a new holding ID can be
assigned and a new thread commenced for that trial. In
this way, the OpenTrials database can facilitate field sur-
veillance for ongoing unregistered and therefore poorly
regulated or unethical research.
Trial sponsors or university research staff may visit the
site to ensure that all their trials have results publicly
available, that all other data are available, and that regis-
try entries are not conflicting. A journalist or policy offi-
cer interested in publication bias may visit the site and
explore the treatments, PIs, sites, or sponsors with the
highest rates of apparently unreported results on com-
pleted trials.
A systematic reviewer seeking to conduct a rapid re-
view may visit the site to search for trials and to aggre-
gate existing extracted structured data from the site to
avoid duplication of effort, before generating structured
data themselves on uncoded trials and then sharing this
data in turn. A researcher working on automating sys-
tematic reviews may use manually extracted structured
data on the site, matched to free text documents, to cali-
brate their automated data extraction algorithms and re-
quest bespoke fields to share their extracted data back to
a hidden part of the site for shared comparisons among
automated review researchers.
Technical issues with data curation from multiple sources
Hosting a broad range of data and documents presents
some challenges around curation, especially because
Goldacre and Gray Trials  (2016) 17:164 Page 7 of 12
Fig. 3 Transparency leader board (using mock data for feedback on proposed design only)
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different sources of structured data will use different for-
mats and different dictionaries. Although we will exploit
available mapping between different data schemas and
dictionaries, we do not expect to necessarily make all
sources of all structured data on all trials commensur-
able and presentable side by side. For example, interven-
tion may be described in free text or as structured data
using various different dictionaries, and even sample size
may be labelled in different ways in different available
datasets, not all of which can necessarily be parsed and
merged. For simplicity, we are imposing a series of
broad categories as our top-level data schema, following
the list given above. This is best thought of as a thread
of documents on a given trial, where a “document”
means either an actual physical document (such as a
consent form or a trial report) or a bundle of structured
data for a trial (such as the structured results page from
a ClinicalTrials.gov entry in XML format or a row of ex-
tracted data with accompanying variable names for a
systematic review). This is for ease of managing multiple
data sources, providing multiple bundles of structured
data about each trial in multiple formats, each of which
may be commonly or rarely used.
Parsers for such bundles of structured data, and mech-
anisms to present it in a user-friendly fashion, will be
built according to need as expressed in our user groups.
For example, we will parse ClinicalTrials.gov results
pages in some detail and extract data on important fea-
tures, such as sample size or primary and secondary out-
comes, to present these on the page, because these data
are consistently structured, well-curated, and available
for a large number of trials. For more uncommon for-
mats of structured data provided by systematic re-
viewers, we will extract some data or give options to
present it on the page attractively (for example, listing
“variable name” and “value”), but we will not present it
on the main page for that trial. For more obscure struc-
tured data, such as the extracted data on a relational
database used by a team of systematic reviewers intern-
ally (many of which may never have been included in a
systematic review or a registry), we will extract some
data from some fields and present these cleanly on the
page but leave the rest available for download. Where
anyone can provide us with a key to accompany their
data schema, explaining what each variable name de-
notes, we will present that alongside their data. Overall,
this approach represents a balance between what is
achievable and perfect data curation, reflecting the fact
that many users of complex structured data will be cap-
able of using that structured data in its more raw forms.
Inconsistent structured data presents a further chal-
lenge, but also an opportunity. For example, “number of
participants” may be slightly different in different data
sources. This presents a challenge in terms of record
linkage validating a match between data sources to en-
sure that both records do pertain to the same trial. It
also presents a challenge in terms of data presentation,
as a choice must be made regarding which to present in
a user-friendly front page for a trial. This is an example
of the issues covered in our user engagement workshops.
However, it also presents an opportunity to identify and
flag inconsistencies in data on the same feature of the
same trial in different places, to facilitate research on the
reasons for this, and to establish whether such inconsist-
encies have resulted in bias.
By comparison, indexing and threading free text docu-
ments present far fewer challenges. For each uploaded
document, we expect to have some metadata covering
provenance, date of upload, type, any available struc-
tured data from the source (subject to the issues above),
and some optional additional extracted data.
Open data in medicine
Open data is a widely recognised concept outside medi-
cine, but to date there has been relatively little activity
around open data in healthcare, and in particular almost
none on clinical trials. The concept of “open data” arose
in the open source software movement and in public
sector information policy work. It now refers to a rapidly
growing set of ideals, norms, and practises for publishing
information from government, academia, civil society,
and the private sector. Open data principles and stan-
dards stipulate how information should be disclosed: in
machine-readable formats, for example, and with open
licenses that remove restrictions on re-use [9]. The
removal of legal and technical restrictions on re-use is
intended to facilitate new forms of collaboration,
innovation and re-use of data, such as through analysis,
new applications and services, or collaborative databases
and data “ecosystems” which combine and curate data
from multiple sources.
Existing notable examples of open data include the
OpenStreetMap project, a collaborative open data pro-
ject to create a free map of the world, integrating geo-
spatial data from many different sources, including the
public sector, private sector, researchers, individuals, and
civil society organisations. To date, this project has over
2 million registered and contributing users, with their
data widely used as an alternative to proprietary geospa-
tial information providers [26]. The Wikidata project, a
sister project to Wikipedia, curates statistical data from
a variety of different sources and currently has had over
230 million edits from 15,000 active users [27]. Both of
these projects have been relatively successful in aligning
the activities of different users to facilitate the collabora-
tive development of a shared resource which can be re-
used and developed in a wide variety of different
contexts. The integration of these projects into different
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applications, services and workflows has also contributed
in turn to their further development, population, and
sustainability.
We hope that the OpenTrials project can become a
similar collaborative open database project for medicine,
and that it can help to catalyse a better data infrastruc-
ture for information about clinical trials. While many
existing databases are limited to specific use cases (such
as for compliance with regulation or for particular re-
search communities), there is an opportunity to create a
shared data infrastructure for medicine through a com-
bination of flexible and extensible schemas and data
structures, user interfaces catering to different users and
use cases, proactively seeking collaboration with organi-
sations and researchers who operate in this area, and be-
ing responsive to their needs. This will entail not just
the technical work of collation, cleaning and presenta-
tion of data from multiple sources but also the social
and political work of aligning the interests and activities
of different organisations, researchers and users around
collaborative activity. Elsewhere, Open Knowledge (the
organisation leading the technical aspects of building the
OpenTrials database) has used the phrase participatory
data infrastructures to describe flexible information sys-
tems—with their various technical, legal, administrative
and social components—that are responsive to the needs
and interests of multiple different users and groups [28].
By being responsive, the data infrastructure can be ex-
tended to include fields and indicators which are not
currently captured in existing information systems,
which can make it more useful as a research resource, a
tool for driving policy change and improvement in data
quality, or for other as yet unforeseen purposes. In
addition to this, the very act of requesting shares of bulk
data can itself be a positive forward push.
As a minimum, we hope that OpenTrials and related
projects will contribute to advancing norms and prac-
tices around access to data and documents in medicine,
including the expectation that such information will be
shared as structured open data that can be more readily
matched, analysed and collaboratively improved.
Intellectual property and privacy
There are various intellectual property (IP) issues pre-
sented by such a database, such as regarding third-party
IP in articles, documentary materials or datasets. There
are various approaches to managing these issues. For ex-
ample, if a copy of a consent form is made available to
us by a trial participant, then we believe there is a clear
public interest in its being publicly accessible and avail-
able for download (with personal information redacted
where needed). However, such forms can be lengthy
written documents published without explicit permis-
sion to republish or re-use. While it seems unlikely that
anyone would have a sincere commercial IP reason to
withhold such documents from public access, it is pos-
sible to have other reasons to prefer that they be kept in-
accessible or to have a blanket policy on restricting
third-party use of all documents or a preference to host
it on their own service; therefore, they may use IP law to
prevent it from being either hosted or shared with doc-
tors, researchers, and patients.
Here we believe the most sensible option is to pursue a
simple three-stage policy: (1) link out to such documents,
wherever possible, if they are publicly accessible in any
form, but take a copy for archive in case the publicly ac-
cessible version disappears; (2) host the text if such docu-
ments are not accessible, assuming good faith and public
interest, but provide a service for “take down” requests;
and (3) treat each request for withdrawal on a case-by-
case basis, seeking funding for legal expenses to defend
public interest as and where this seems appropriate.
With respect to privacy, we propose to avoid hosting
IPD to protect patient privacy. Instead, we will link to
sources where IPD is available upon request and moni-
tor the availability of these sources.
Practical issues
The project has received phase I funding from the Laura
and John Arnold Foundation, given to Open Knowledge
and the Centre for Open Science, with BG as principal
investigator. User engagement, database design, front-
end design and coding will be carried out by Open
Knowledge, and the back-end database is provided by
the Centre for Open Science. We have a small steering
committee meeting regularly for the daily running of the
project and a larger advisory group with a wide range of
users and stakeholders for intermittent guidance on build,
strategic direction and sustainability. In terms of outcome
measures, we have targets for the quantity of data
imported and the number of active users, as well as policy
impacts, such as raised expectations of access to docu-
ments and around structured open data on clinical trials.
Our objective for phase I is to create a functioning data-
base with a practical schema; populate it through scraping,
record linkage, data donations, crowd-sourcing, and a
small amount of pilot curation; and create user-friendly
web interfaces onto the data. We believe that this will pro-
vide a clear working demonstration of the value of a
matched and indexed database of all structured data and
documents on all clinical trials, and that it will enable us
to work towards obtaining further funding to populate the
database—the key financial challenge—and develop new
features to meet demand from researchers, clinicians, pol-
icy makers, patients and other users. We are also consid-
ering alternative options for sustainability, such as offering
a paid service whereby OpenTrials librarians can curate
and enter data as perfectly as possible for a given set of
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trials in exchange for a fee, enabling research sites or
sponsors to facilitate access to information on their trials
and demonstrate compliance and transparency, although
this raises potential conflicts of interest that would need
to be managed. If, after producing a functioning service, it
proves impossible to make the project financially sustain-
able, then we have a no-cost wind-down plan in place,
sharing all code and data to appropriate platforms (e.g.,
GitHub and Figshare). Where further features and in-
frastructure have been developed using functions on
the site, we will aim to reserve a fund to permit a
static archive with functioning APIs so that any other
projects dependent on OpenTrials features or data
can continue to operate.
There are several clear shortcomings and challenges to
the OpenTrials plan which we have attempted to miti-
gate within the confines of limited funding as described
above. These challenges include limitations on financial
and person-time resources that prevent us from creating
a comprehensive, manually curated library of all infor-
mation on all trials; the challenges around ensuring
integrity of material submitted openly online; the chal-
lenges of maintaining information infrastructure over a
term that exceeds stand-alone academic project grants;
and the challenges around engaging a community to so-
licit wider sharing of documents and structured data.
We are keen to hear feedback on additional strategies to
meet these challenges.
Conclusions
We are building an open free database and web service
to identify, aggregate, store, match, index and share all
available documents and data on all clinical trials. We
are keen to receive feedback on the current methods,
design, and data schema; feature requests; offers or sug-
gestions of further data sources; and collaborations or
methods to expand or improve the specification. Progress
can be viewed at www.OpenTrials.net where the service
will be hosted.
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